Investigational drug · Phase 3
ICP-488
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Plaque Psoriasis Patients, Primary Sjögren's Syndrome, Cutaneous Lupus Erythematosus (CLE).
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "ICP-488"
First trial start
2025
Mar 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ICP-488", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plaque Psoriasis Patients
- Primary Sjögren's Syndrome
- Cutaneous Lupus Erythematosus (CLE)
Approved drugs for the same conditions: Plaque psoriasis · Immunology and inflammation · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ICP-488" as an intervention, largest first.
- Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT06842199 · 383 participants (planned) · Start Mar 20, 2025 · Primary completion May 2026
Drug: ICP-488 Tablets; ICP-488 Placebo · For: Plaque Psoriasis Patients
Sites: Hefei, China; Wuhu, China; Beijing, China · 46 sites in all
- A Study to Evaluate the Efficacy and Safety of ICP-488 in Participants With Primary Sjögren's SyndromePivotal-lookingNot yet recruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07727486 · 240 participants (planned) · Start Aug 2026 · Primary completion Dec 2028
Drug: ICP-488 Tablets; ICP-488 Placebo · For: Primary Sjögren's Syndrome
Sites: Beijing, China; Chongqing, China; Xiamen, China · 22 sites in all
- A Clinical Study of ICP-488 in Healthy Subjects and Patients With PsoriasisPivotal-lookingStatus unknown
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT05451199 · 154 participants (planned) · Start Jul 29, 2022 · Primary completion Oct 30, 2023
Drug: ICP-488; Placebo · For: Psoriasis
Sites: Hefei, China; Shijiazhuang, China; Nanyang, China · 7 sites in all
- Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT06109818 · 129 participants · Start Jan 4, 2024 · Primary completion Aug 5, 2024
Drug: ICP-488 Tablets; ICP-488 Placebo · For: Moderate to Severe Plaque Psoriasis
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 31 sites in all
- Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind StudyPivotal-lookingRecruiting
Beijing InnoCare Pharma Tech Co., Ltd.Industry
NCT07440537 · 105 participants (planned) · Start Apr 27, 2026 · Primary completion Mar 2027
Drug: ICP-488 Tablets; ICP-488 Tablets · For: Cutaneous Lupus Erythematosus (CLE)
Sites: Hefei, China; Beijing, China; Chongqing, China · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The Role of TYK2 Inhibitors in the Pathogenesis and Treatment of Psoriasis.
Burshtein J, Schlesinger T · J Clin Aesthet Dermatol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.